FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 348:1835-1837 May 8, 2003 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hays, J. PubMed Citation

Over the past two decades, multiple observational studies have suggested that postmenopausal hormone therapy reduces the risks of osteoporotic fractures and coronary heart disease. On the basis of this evidence, hormone therapy was often recommended for women who were at high risk for fractures and coronary disease. But these recommendations were based entirely on observational evidence, which can sometimes be misleading if the groups being compared have different risk patterns and lifestyles. In the early to mid-1990s, several large, randomized trials were initiated to provide definitive evidence concerning the risks and benefits of hormone therapy for the prevention of disease. . . . [Full Text of this Article]

Source Information

From the Departments of Epidemiology and Biostatistics and of Medicine, University of California, San Francisco, and the San Francisco Veterans Affairs Medical Center, San Francisco.

This article was published at www.nejm.org on March 17, 2003.

This article has been cited by other articles:

• Keller, K. B., Lemberg, L. (2005). Estrogen Plus Progestin, Benefits and Risks: The "Women's Health Initiative" Trials. Am J Crit Care 14: 157-160 [Full Text]  
• Crawford, F., Langhorne, P. (2005). Time to review all the evidence for hormone replacement therapy. BMJ 330: 345-345 [Full Text]  
• Peterson, H. B., Thacker, S. B., Corso, P. S., Marchbanks, P. A., Koplan, J. P. (2004). Hormone Therapy: Making Decisions in the Face of Uncertainty. Arch Intern Med 164: 2308-2312 [Full Text]  
• Bouxsein, M. L., Kaufman, J., Tosi, L., Cummings, S., Lane, J., Johnell, O. (2004). Recommendations for Optimal Care of the Fragility Fracture Patient to Reduce the Risk of Future Fracture. J Am Acad Orthop Surg 12: 385-395 [Abstract] [Full Text]  
• Gomes, M. P. V., Deitcher, S. R. (2004). Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review. Arch Intern Med 164: 1965-1976 [Abstract] [Full Text]  
• (2004). Summary of Balancing Risks and Benefits. Obstet Gynecol 104: 128S-129S [Full Text]  
• Keating, N. L., Ayanian, J. Z. (2003). Challenges and opportunities for primary care evaluation. Int J Qual Health Care 15: 371-373 [Full Text]  
• Herrington, D. M., Howard, T. D. (2003). From Presumed Benefit to Potential Harm -- Hormone Therapy and Heart Disease. NEJM 349: 519-521 [Full Text]  
• Zacharski, L. R, Gerhard, G. S (2003). Perspective: Atherosclerosis: a manifestation of chronic iron toxicity?. Vasc Med 8: 153-155  
• (2003). Combination HRT Continues to Come Up Empty. Journal Watch Cardiology 2003: 1-1 [Full Text]  
• (2003). Does Estrogen/Progestin Therapy Improve Quality of Life?. Journal Watch Dermatology 2003: 12-12 [Full Text]  
• (2003). Does Estrogen/Progestin Therapy Improve Quality of Life?. JWatch General 2003: 1-1 [Full Text]